NCT00442533View on ClinicalTrials.gov

Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

August 30, 2014

Study Completion Date

December 28, 2015

Conditions
Neuroendocrine Tumors
Interventions
DRUG

Indium-111 pentetreotide

4 cycles of 500 mCi treatments every 10-12 weeks

Trial Locations (2)

77042

Excel Diagnostic Imaging Clinics, Houston

77225-0269

St. Lukes Episcopal Hospital, Houston

Sponsors
All Listed Sponsors
collaborator

Excel Diagnostic Imaging Clinics

UNKNOWN

collaborator

Radiomedix, Inc.

INDUSTRY

collaborator

CHI St. Luke's Health, Texas

OTHER

lead

Radio Isotope Therapy of America

OTHER